Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVIMMUNAGE: Factors influencing the COVID-19 vaccine immune response according to age and prior COVID-19
2021-003547-24Phase 4Completed
- Sponsor
- CHU Saint-Etienne
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of tozinameran and elasomeran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by CHU Saint-Etienne. Primary endpoint: Anti-SARS-CoV-2-specific neutralizing antibody. Started Jun 2021; status: completed.
02
Drugs
tozinameranelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-003547-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003547-24.